Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.60 EUR
Change Today -0.151 / -5.49%
Volume 0.0
IV1 On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 10:10 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

erba diagnostics inc (IV1) Snapshot

Open
€2.59
Previous Close
€2.75
Day High
€2.60
Day Low
€2.57
52 Week High
03/23/15 - €3.67
52 Week Low
04/29/14 - €1.00
Market Cap
114.3M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
44.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ERBA DIAGNOSTICS INC (IV1)

Related News

No related news articles were found.

erba diagnostics inc (IV1) Related Businessweek News

No Related Businessweek News Found

erba diagnostics inc (IV1) Details

ERBA Diagnostics, Inc., through its subsidiaries, develops, manufactures, and markets diagnostic test kits or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing. It manufactures scientific and laboratory instruments, such as Mago 4, Mago 4S, and Mago Plus systems, which perform tests in an automated mode; sells other diagnostic products in Italy; and develops, manufactures, and markets diagnostic equipment, as well as raw materials, such as antigens that are used in the production of diagnostic kits. The company also develops, manufactures, and markets autoimmune reagents and research products for use by research laboratories and commercial diagnostic manufacturers. In addition, the company provides instruments for blood cell counting and blood analysis; supplies reagents and other consumable materials; sells diabetic testing products, including the DS5 instrument, dispenser, and associated reagent kits, which measure long-term glucose control in diabetic patients; and offers equipment for use in the field of human and veterinary hematology. Further, it manufactures and sells liquid stable, diagnostics chemistry reagents used for in vitro diagnostics testing. The company markets its products through its sales force to hospitals, reference laboratories, clinical laboratories, and research laboratories, as well as to other commercial companies that manufacture diagnostic products in the United States; and through sales representatives and independent agents in Italy, as well as through independent distributors internationally. ERBA Diagnostics, Inc. was founded in 1980 and is headquartered in Miami Lakes, Florida. ERBA Diagnostics, Inc. is a subsidiary of ERBA Diagnostics Mannheim GmbH.

135 Employees
Last Reported Date: 04/14/14
Founded in 1980

erba diagnostics inc (IV1) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $150.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $47.4K
Compensation as of Fiscal Year 2013.

erba diagnostics inc (IV1) Key Developments

Prakash Patel to Resign as Controller, Principal Financial Officer and Principal Accounting Officer of ERBA Diagnostics, Inc

On April 13, 2015, Prakash Patel, the Controller, Principal Financial Officer and Principal Accounting Officer of ERBA Diagnostics, Inc., delivered notice to the company of his intention to resign effective as of April 30, 2015.

ERBA Diagnostics Announces Notice Of Non-Compliance With NYSE MKT Continued Listing Standards

ERBA Diagnostics, Inc. announced that, on April 17, 2015, the Company received a letter from NYSE MKT LLC stating that the Exchange has determined that the Company is not in compliance with Sections 134 and 1101 of the Exchange’s Company Guide due to the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2014 with the Securities and Exchange Commission. The letter also states that the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2014 is a material violation of its listing agreement with the Exchange and, therefore, pursuant to Section 1003(d) of the Company Guide, the Exchange is authorized to suspend and, unless prompt corrective action is taken, remove the Company’s securities from the Exchange. The Exchange has informed the Company that, in order to maintain its listing on the Exchange, the Company must, by May 1, 2015, submit a plan of compliance addressing how it intends to regain compliance with Sections 134 and 1101 of the Company Guide by July 16, 2015. If the Company’s Plan is accepted by the Exchange, then the Company may be able to continue its listing during the Plan Period, during which time it will be subject to periodic review to determine whether it is making progress consistent with the Plan. If the Company’s Plan is not accepted by the Exchange, then the Company will be subject to delisting proceedings. Furthermore, if the Plan is accepted by the Exchange, but the Company is not in compliance with the continued listing standards of the Company Guide by July 16, 2015, or if the Company does not make progress consistent with the Plan during the Plan Period, then the Exchange staff will initiate delisting proceedings as appropriate. The Company is working diligently to submit the Plan by May 1, 2015 and to regain compliance with the Company Guide by July 16, 2015. As previously disclosed in its Notification of Late Filing on Form 12b-25 filed with the SEC on April 1, 2015, the Company has delayed filing its Annual Report on Form 10-K for the year ended December 31, 2014 because of unforeseen delays in connection with completing and filing the Company’s consolidated financial statements and the accompanying footnotes. Until these matters can be resolved, the Company will not be in a position to file its Annual Report on Form 10-K for the year ended December 31, 2014 with the SEC. Pursuant to Rule 12b-25 under the Securities Exchange Act of 1934, the Company received an extension until April 15, 2015 to file its Annual Report on Form 10-K for the year ended December 31, 2014, which extension has now expired. The Company is working diligently to complete and file its Annual Report on Form 10-K for the year ended December 31, 2014 with the SEC, which, as previously disclosed, the Company expects to do on or about April 30, 2015.

ERBA Diagnostics, Inc. announced delayed annual 10-K filing

On 04/01/2015, ERBA Diagnostics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IV1:GR €2.60 EUR -0.151

IV1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $49.97 USD -0.04
Bio-Rad Laboratories Inc $137.41 USD +0.01
DiaSorin SpA €41.09 EUR +0.17
Meridian Bioscience Inc $19.13 USD +0.33
View Industry Companies
 

Industry Analysis

IV1

Industry Average

Valuation IV1 Industry Range
Price/Earnings 100.0x
Price/Sales 4.5x
Price/Book 6.9x
Price/Cash Flow 87.7x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ERBA DIAGNOSTICS INC, please visit www.erbadiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.